
SEP-363856 hydrochloride
CAS No. 1310422-41-3
SEP-363856 hydrochloride( SEP-856 hydrochloride )
Catalog No. M22443 CAS No. 1310422-41-3
SEP-363856 hydrochloride is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia. SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 224 | In Stock |
![]() ![]() |
10MG | 374 | In Stock |
![]() ![]() |
25MG | 623 | In Stock |
![]() ![]() |
50MG | 887 | In Stock |
![]() ![]() |
100MG | 1197 | In Stock |
![]() ![]() |
500MG | 2394 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameSEP-363856 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionSEP-363856 hydrochloride is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia. SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor.
-
DescriptionSEP-363856 hydrochloride is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia. SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor.SEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active. SEP-856 exhibits a behavioral signature similar to known antipsychotic drugs.PCP-induced hyperactivitysignificantly reduced by SEP-856 (0.3, 1 and 10 mg/kg, orally once) . Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time.(In Vitro):SEP-856 (10 μM) shows >50% inhibition of specific binding at α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors.(In Vivo):SEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs.SEP-856 (0.3, 1 and 10 mg/kg, orally once) significantly reduces PCP-induced hyperactivity. Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time.
-
In VitroSEP-856 (10 μM) shows >50% inhibition of specific binding at α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors.
-
In VivoSEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs.SEP-856 (0.3, 1 and 10 mg/kg, orally once) significantly reduces PCP-induced hyperactivity.?Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time. Animal Model:Acute treatment with phencyclidine (PCP), which induces robust hyperactivity in rodents.Dosage:0.3, 1 and 3 mg/kg.Administration:Orally once.Result:Resulted in a dose-dependent inhibition of PCP-induced hyperactivity responses in C57Bl/6J mice (1-way ANOVA F (5, 59) = 18.96, p < 0.0001; Tukey’s post-hoc test, p < 0.05) with a 50% effective dose (ED50) of approximately 0.3 mg/kg.Animal Model:Male Sprague Dawley rats.Dosage:1, 2, and 5 mg/kg.Administration:I.V. injection. (Pharmacokinetic Analysis).Result:Rapidly absorbed with maximum plasma and brain concentrations reached within 0.25 to 0.5 hours in mice and rats and maximum plasma concentrations reached within 6 ± 2.83 hours in monkeys.Penetrated mouse and rat brains after oral administration (10 mg/kg), with average brain-to-plasma AUC ratios of ~3 respectively.
-
SynonymsSEP-856 hydrochloride
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
Recptor5-HT1A Receptor|5-HT1B Receptor|5-HT1D Receptor|5-HT2A Receptor|5-HT2C Receptor|5-HT7 Receptor|TAAR1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1310422-41-3
-
Formula Weight219.73
-
Molecular FormulaC9H14ClNOS
-
Purity>98% (HPLC)
-
SolubilityDMSO:62.5 mg/mL (284.44 mM; Need ultrasonic)
-
SMILESCl.CNC[C@@H]1OCCc2ccsc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
Gamabufotalin
Gamabufotalin, a major bufadienolide of Chansu, has been used for treatment of COX-2-mediated diseases and cancer therapy due to its desirable metabolic stability and less adverse effect.
-
NLX-204 hydrochlorid...
NLX-204 hydrochloride is a potent and selective ERK1/2 phosphorylation-preferring serotonin 5 HT1A receptor agonist(pKi = 10.19).NLX-204, displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein.
-
Homoeriodictyol
Homoeriodictyol, a naturally occurring, bitter-masking flavanone, as a promising agent to increase appetite and food intake. The flavanone homoeriodictyol can increase SGLT-1-mediated glucose uptake but decrease serotonin release in differentiated Caco-2 cells.In contrast to other polyphenols, the flavanon Homoeriodictyol promotes glucose uptake by 29.0 ± 3.83% at a concentration of 100 μM.